Here are the 424B prospectus supplements from Scinai Immunotherapeutics Ltd. (SCNI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SCNI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCNI filings page.
Scinai Immunotherapeutics Ltd. is registering for resale up to 16,344,037 American Depositary Shares (ADSs) — each ADS representing 4,000 ordinary shares — for the selling shareholders under a resale prospectus. The selling shareholders, not the Company, will receive all proceeds from any resale; the Company will receive proceeds only to the extent the underlying Warrants are exercised for cash.
The prospectus covers ADSs issuable upon exercise of multiple warrant tranches and related instruments and states that, if all Warrants were exercised for cash, the Company would receive approximately $5.7 million. The ADSs trade on Nasdaq under SCNI (last reported sale price $0.56 on May 18, 2026), and the Company disclosed a Nasdaq minimum-bid-price non-compliance notice with an initial cure period through September 8, 2026.